Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b

Table 1 Clinical features of the patients who achieved sustained virologic response 12 with DCV + ASV or SOF + LDV

Therapy regimen	DCV + ASV	SOF + LDV	P value
Number	121	132
SVR 12	85.8%	97.7%
Gender (M:F)	59:62	49:83	0.075
	mean ± SD	mean ± SD
Age (yr)	68.4 ± 11.8	66.7 ± 13.1	0.280
AST (IU/L)	56.4 ± 39.6	51.7 ± 33.3	0.300
ALT (IU/L)	51.9 ± 40.5	46.5 ± 38.3	0.270
Hb (g/dL)	13.3 ± 1.7	13.3 ± 1.7	0.830
Plt (104/μL)	13.9 ± 5.9	15.5 ± 7.0	< 0.05
Alb (g/dL)	3.9 ± 0.53	4.0 ± 0.45	< 0.05
T-Bil (mg/dL)	0.87 ± 0.57	0.76 ± 0.39	0.086
PT (%)	88.6 ± 15.6	90.4 ± 13.7	0.330
TC (mg/dL)	163.7 ± 33.3	171.1 ± 34.9	0.087
TG (mg/dL)	113.4 ± 83.0	112 ± 58.9	0.870
LDL-C (mg/dL)	82.8 ± 27.2	89.2 ± 28.5	0.068
HDL-C (mg/dL)	55.5 ± 18.4	58.7 ± 17.6	0.160
HCV-RN A (log•IU/mL)	5.9 ± 0.78	5.9 ± 0.87	0.960
Fib4 index	4.9 ± 3.3	4.7 ± 4.0	0.640

DCV: Daclatasvir; ASV: Asunaprevir; SOF: Sofosbuvir; LDV: Ledipasvir; SVR12: Sustained virologic response after 12 wk from the end of therapy; AST: Asparate-2-oxoglutarate aminotransferase; ALT: Alanine-2-oxoglutarate aminotransferase; Hb: Hemoglobin; Plt: Platelet; Alb: Albumin; T-Bil: Total bilirubin; PT: Prothrombin time; TC: Total cholesterol; TG: Triglyceride; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; HCV-RNA: Hepatitis C virus ribonucleic acid; Fib4 index: Fibrosis 4 index.